Nick Leschly

Nick Leschly is chief executive officer at 2seventy bio. Previously, Nick served as chief bluebird at bluebird bio for 11 years. Prior to bluebird, he was a partner and founding member of Third Rock Ventures in 2007. Nick played an integral role in the overall formation, development, and business strategy of several of Third Rock’s portfolio companies, including Agios Pharmaceuticals, Inc. and Edimer Pharmaceuticals, Inc. Prior to joining Third Rock, Nick worked at Millennium Pharmaceuticals, Inc., leading several early-stage drug development programs and served as the product leader for VELCADE. Nick received his B.S. in molecular biology from Princeton University and his MBA from Wharton Business School. He currently serves as a board member of the Biotechnology Innovation Organization (BIO).